Luteolin overcomes acquired resistance to osimertinib in non-small cell lung cancer cells by targeting the HGF-MET-Akt pathway.
Am J Cancer Res
; 13(9): 4145-4162, 2023.
Article
in En
| MEDLINE
| ID: mdl-37818074
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
Am J Cancer Res
Year:
2023
Document type:
Article